Taken together, these prototype data suggest that PMS treatment preferentially impairs viability of vemurafenib-resistant human malignant melanoma cells with induction of caspase-dependent PARP1-cleavage, an observation consistent with the reported hypersensitivity of vemurafenib-resistant melanoma cells to mitochondriotoxic therapeutic intervention. The gene discussed is PARP1; the disease is melanoma.